Weight lifted for Arena: Eisai launches Belviq
This article was originally published in Scrip
Executive Summary
The first new competitor for the Vivus weight loss therapy Qsymia (topiramate and phentermine) will hit the market on 11 June when the Arena Pharmaceuticals and Eisai drug Belviq (lorcaserin) will be available in US pharmacies.